




**Urgent Field Safety Notice (FSN)**  
**Remel RapID™ NF System**

<b>1. Information on Affected Devices*</b>	
1.	1. Device Type(s)* IVD
1.	2. Commercial name(s) RapID NF Plus System
1.	3. Unique Device Identifier(s) (UDI-DI) 00848838058158
1.	4. Primary clinical purpose of device(s)* Remel RapID™ NF Plus System is a qualitative micromethod employing conventional and chromogenic substrates for the identification of medically important glucose non-fermenting, Gram-negative bacteria and other select glucose-fermenting, Gram-negative bacteria not belonging to the family Enterobacteriaceae, which have been isolated from human clinical specimens. A complete listing of the organisms addressed by the RapID NF Plus System is provided in the RapID NF Plus Differential Chart (found in the IFU).
1.	5. Device Model/Catalogue/part number(s)* R8311005
1.	6. Software version N/A
1.	7. Affected serial or lot number range 3364798, 3364799, 3364800, 3381406, 3390383, 3442256 and 3442431
1.	8. Associated devices N/A

<b>2. Reason for Field Safety Corrective Action (FSCA)*</b>	
2.	1. Description of the product problem* A technical investigation has determined ATCC 19606 ( <i>Acinetobacter baumannii</i> ATCC® 19606), ATCC 13253 ( <i>Elizabethkingia meningoseptica</i> ATCC® 13253) and blank (NF reagent) gave a positive reaction where it should have given a negative reaction within the NO <sub>3</sub> well of the panel.
2.	2. Hazard giving rise to the FSCA* The NO <sub>3</sub> well is giving the incorrect reaction with certain strains.
2.	3. Probability of problem arising High
2.	4. Predicted risk to patient/users There should be no immediate or long-term health consequences from using this product. The determination of nitrate in the affected species are not the sole determinant for identification of these species. There are some strains of both <i>A. baumannii</i> and <i>E meningosepticum</i> that are positive for NO <sub>3</sub> , so the entire range of biochemical tests should be considered in the identification of clinical specimens. In this context of a single false positive test, the clinical risk should be considered negligible.
2.	5. Further information to help characterise the problem N/A

2.	6. Background on Issue				
	Internal investigation from on-going stability.				
2.	7. Other information relevant to FSCA				
	<b>Product Code</b>	<b>Kit Lot Number</b>	<b>Panel Lot Number</b>	<b>Expiry</b>	<b>Manufactured Date</b>
	R8311005	3364798	3364789	11.07.2022	19.10.2021
		3364799	3364790	19.07.2022	02.11.2021
		3364800	3364791	15.08.2022	08.12.2021
		3381406	3389376	06.09.2022	14.12.2021
		3390383	3389922	02.11.2022	10.02.2022
		3442256	3442254	02.12.2022	11.03.2022
		3442431	3442429	28.12.2022	08.04.2022

3. Type of Action to mitigate the Risk*		
3.	1. Action To Be Taken by the User*	
	<input checked="" type="checkbox"/> Identify Device <input type="checkbox"/> Quarantine Device <input type="checkbox"/> Return Device <input checked="" type="checkbox"/> Destroy Device  <input type="checkbox"/> On-site device modification/inspection  <input checked="" type="checkbox"/> Follow patient management recommendations  <input type="checkbox"/> Take note of amendment/reinforcement of Instructions For Use (IFU)  <input type="checkbox"/> Other <input type="checkbox"/> None	
3.	2. By when should the action be completed?	Immediately
3.	3. Particular considerations for: IVD	
	Is follow-up of patients or review of patients' previous results recommended? Yes	
	We request that the requirement for review of reported test results should be determined by the appropriate technical expert	
3.	4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes
3.	5. Action Being Taken by the Manufacturer	
	<input checked="" type="checkbox"/> Product Removal <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Software upgrade <input type="checkbox"/> IFU or labelling change <input type="checkbox"/> Other <input type="checkbox"/> None	
3	6. By when should the action be completed?	As soon as possible
3.	7. Is the FSN required to be communicated to the patient /lay user?	No
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?	
	Choose an item.            Choose an item.	

4. General Information*		
4.	1. FSN Type*	New
4.	2. For updated FSN, reference number and date of previous FSN	N/A
4.	3. For Updated FSN, key new information as follows:	
	N/A	
4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet
4	5. If follow-up FSN expected, what is the further advice expected to relate to:	
	N/A	
4	6. Anticipated timescale for follow-up FSN	N/A
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)	
	a. Company Name	Thermo Fisher Scientific
	b. Address	Clipper Boulevard West, Cross ways industrial estate, Dartford, Kent. DA2 6PT
	c. Website address	www.thermofisher.com
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *	
4.	9. List of attachments/appendices:	Customer response form
4.	10. Name	<b>Mark Chamberlain</b> <b>Vice President, Quality and Regulatory</b> <b>Microbiology Products</b>
	Signature	

Transmission of this Field Safety Notice	
	<p>This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate).</p> <p>Please transfer this notice to other organisations on which this action has an impact. (As appropriate).</p> <p>Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.</p> <p>Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.*</p>

### Customer Reply Form

1. Field Safety Notice (FSN) information			
FSN Reference number*	2022-008		
FSN Date*	22 July 2022		
Product/ Device name*	Remel RapID™ NF System		
Product Code(s)	R8311005		
Batch/Serial Number (s)	3364798, 3364799, 3364800, 3381406, 3390383, 3442256 and 3442431		
2. Customer Details			
Account Number			
Organisation Name*			
Organisation Address*			
Department/Unit			
Shipping address if different to above			
Contact Name*			
Title or Function			
Telephone number*			
Email*			
3. Customer action undertaken on behalf of Healthcare Organisation			
<input type="checkbox"/>	I confirm receipt of the Field Safety Notice and that I read and understood its content.		
<input type="checkbox"/>	I performed all actions requested by the FSN.		
<input type="checkbox"/>	The information and required actions have been brought to the attention of all relevant users and executed.		
<input type="checkbox"/>	I have returned affected devices - enter number of devices returned and date complete or <b>N/A</b>	Qty:	Lot/Serial Number:      Date Returned (DD/MM/YY)
		Comments:	
<input type="checkbox"/>	I have destroyed affected devices – enter number destroyed and date complete.	Qty:	Lot/Serial Number:      Date Returned (DD/MM/YY)
		Qty	Credit <input type="checkbox"/> Replacement <input type="checkbox"/>
		Comments:	
<input type="checkbox"/>	No affected devices are available for return/ destruction		
<input type="checkbox"/>	Other Action (Define):		
<input type="checkbox"/>	I do not have any affected devices.		
<input type="checkbox"/>	I have a query please contact me (e.g. need for replacement of the product).		
Print Name*			
Signature*			
Date*			

<b>4. Return acknowledgement to sender</b>	
Email	<a href="mailto:MBD.vigilance@thermofisher.com">MBD.vigilance@thermofisher.com</a>
Telephone Number & Fax	Tel : +44(0) 1256 841144 Fax :+44(0) 1256 479525
Postal Address	
Deadline for returning the reply form*	<b>12 August 2022</b>

Mandatory fields are marked with \*

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.